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Abstract Context: Dietary management is the mainstay of
effective treatment in PKU, but dietary restriction is
difficult and additional treatment options are needed.
Objective: To systematically review evidence regarding
sapropterin (BH4) use as an adjunct to dietary restriction in
individuals with PKU.
Data Sources: Five databases including MEDLINE up to
August 2011.
Study Selection: Two reviewers independently assessed
studies against predetermined inclusion/exclusion criteria.
Data Extraction: Two reviewers independently extracted
data regarding participant and intervention characteristics
and outcomes and assigned overall quality and strength of
evidence ratings based on predetermined criteria.
Results: BH4 research includes two randomized con-
trolled trials (RCTs) and three uncontrolled open-label
trials. Phenylalanine (Phe) levels were reduced by at least
30 % in up to half of treated participants (32–50 %). In one
RCT comparing placebo on likelihood of a 30 % reduction
in Phe, 9 % of those on placebo achieved this effect,
compared with 44 % of the treated group after 6 weeks. Phe
tolerance and variability were improved in treated partic-
ipants in studies assessing those outcomes. No comparative
studies assessed long-term outcomes including cognitive
effects, nutritional status, or quality of life.
Conclusions: Adjuvant pharmacologic therapy has
the potential to support individuals in achieving optimal
Phe levels. BH4 has been shown to reduce Phe levels in
some individuals, with significantly greater reductions seen
in treated versus placebo groups. The strength of the
evidence is moderate for short-term effects on reducing
Phe in a subset of initially BH4-responsive individuals,
moderate for a lack of significant harms, low for longer-
term effects on cognition, and insufficient for all other
outcomes.
Introduction
Approximately 1 in 13,500–19,000 infants in the United
States is born with phenylketonuria (PKU) (Hegge et al.
2009; National Institutes of Health 2001). Individuals
with PKU have defective phenylalanine hydroxylase
activity, leading to a toxic accumulation of phenylalanine
(Phe) in the blood and multiple tissues (Webster and
Wildgoose 2010) and potentially to intellectual disability,
delayed speech, seizures, and behavior abnormalities (Erbe
and Levy 2002; Wilcox and Cederbaum 2002; Fisch and
Stassart 2004).
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The mainstay for treatment of PKU is a diet that restricts
the intake of Phe to control the Phe concentration in the
blood. In general, the usual treatment goal is a blood Phe
level of 120 to 360 mmol/L (National Institutes of Health
2001; Poustie and Wildgoose 2010). In addition to the low-
Phe diet, patients replace nutrients that are absent in their
restricted diet with Phe-free medical foods (Giovannini
et al. 2007). With adherence to a Phe-restricted diet, poor
outcomes can be mitigated. While advances in dietary
management are improving outcomes for individuals with
PKU, management of PKU can be difficult and onerous,
leading to interest in identifying new ways of managing this
lifelong condition. (Demirkol et al. 2011; Harding and Blau
2010; Blau et al. 2010; Giovannini et al. 2012)
In 2007, the United States Food and Drug Administra-
tion (FDA) approved sapropterin dihydrochloride
(Kuvan®, formerly known as Phenoptin), the first pharma-
cologic treatment for PKU, under the stipulation that
additional studies be conducted on efficacy and long-term
safety. The goal of treatment with sapropterin dihydro-
chloride (hereafter, BH4) is to control blood Phe concen-
trations. Although treatment with BH4 would potentially
allow a relaxation of the low-Phe diet, it is not intended to
serve as a complete substitute for dietary intervention
(Somaraju and Merrin 2010).
The mechanism of action of BH4 is as a cofactor of the
phenylalanine hydroxylase (PAH) enzyme, increasing the
activity level of the enzyme and increasing the amount of
Phe that can be converted to tyrosine. Hypothetically, it
should be more effective in individuals with residual PAH
activity than in individuals with negligible to no enzyme
activity. Typically, a BH4 loading test is performed to
identify potential candidates who are most likely to benefit
from treatment. Loading tests used in practice and in
research vary in terms of target reduction (e.g., 30 %
reduction in blood Phe level) and timeframe, and none has
been established as optimal for identifying those patients
who respond to treatment.
As part of a systematic review of adjuvant therapies for
individuals with PKU, we reviewed the literature on BH4
use in individuals with PKU. The full review is available at
http://www.effectivehealthcare.ahrq.gov.
Methods
Data Sources and Search Strategy
We searched the MEDLINE® (via the PubMed interface),
PsycINFO, EMBASE, Cumulative Index of Nursing and
Allied Health Literature, and the National Agricultural
Library (AGRICOLA) databases. Our search strategies
used a combination of subject heading terms appropriate
for each database and key words relevant to PKU (e.g.,
phenylketonuria, pharmaceutical preparations, phenylala-
nine). We limited searches to the English language but did
not set a date limit. We also manually searched the
reference lists of included studies and of recent narrative
and systematic reviews and meta-analyses addressing PKU.
Study Selection
We developed study inclusion and exclusion criteria in
consultation with an expert panel of clinicians and
researchers involved in treating or studying PKU. We
included all study designs excepting individual case reports
and required that studies include at least 10 individuals with
PKU receiving BH4 for therapy after having shown
positive results on a loading test.
Data Extraction and Synthesis
Using standardized forms, two investigators independently
extracted data regarding study design; study populations;
intervention and comparison groups; and baseline and
outcome data, as well as data about harms or adverse
effects. Principal outcomes of interest included cognitive
and nutritional outcomes, quality of life, and ability to
liberalize the diet while maintaining acceptable Phe levels.
We also extracted data on the intermediate outcomes of
Phe level, Phe tolerance (total Phe intake by weight an
individual can tolerate while maintaining acceptable blood
Phe concentration), and blood Phe variability. We present a
descriptive analysis of the data given the low number of
studies identified and variability in outcomes assessed,
which precluded meta-analysis.
Quality Assessment
Two investigators independently assessed each study using
quality assessment questions as appropriate for each study
design. We adapted questions from quality tools including
the Cochrane Risk of Bias tool. We evaluated the overall
strength of the evidence (degree of confidence that the
observed effect of an intervention is unlikely to change) for
the primary outcomes. We used the approach to determine
strength of evidence as described in the Agency for
Healthcare Research and Quality Effective Health Care
Program’s Methods Guide for Effectiveness and Compara-
tive Effectiveness Reviews (Agency for Healthcare Research
and Quality 2008). We assessed the strength of evidence for
key outcomes identified as the most clinically important:
cognitive outcomes including IQ and executive function,
nutritional outcomes, quality of life, and liberalization of
diet. Secondary outcomes included changes in blood Phe
levels, Phe variability, and Phe tolerance.
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Assessments were based on consideration of the domains
of risk of bias, consistency in direction of the effect,
directness in measuring intended outcomes, and precision
of effect (Table 1). We determined the strength of evidence
separately for major intervention-outcome pairs using an
approach described in more detail in the full review.
Results
Overview of Study Characteristics
Ten studies evaluated the effects of BH4 in participants
with PKU (Table 2, Fig. 1) (Burton et al. 2010, 2011; Levy
et al. 2007; Lee et al. 2008; Trefz et al. 2009, 2010; Vernon
et al. 2010; Burlina and Blau 2009; Lambruschini et al.
2005; Humphrey et al. 2011). Although study populations
overlap, the studies were conducted as separate studies and
thus are presented as such in our analysis. Four of the
studies are linked by common participants: two are
multisite placebo-controlled randomized trials (RCTs) that
contributed to FDA approval of BH4 (Levy et al. 2007;
Trefz et al. 2009). One additional uncontrolled open-label
trial was conducted separately from the family of studies
(Vernon et al. 2010) as were one prospective cohort study
(Humphrey et al. 2011), two retrospective case series
(Burlina and Blau 2009; Burton et al. 2010), and two
prospective case series (Lambruschini et al. 2005; Trefz
et al. 2010).
The studies included up to 80 participants in the
treatment arm, and the total number of individuals in all
studies was 284, after accounting for duplication in
participants across studies. The studies were performed in
the United States, Canada, Australia, and Europe. Partic-
ipants ranged in age from 3 to 58 years in the five trials and
from birth to 34 years in the observational studies. Most
participants had demonstrated responsiveness to BH4 in a
loading study before being assessed for effectiveness
response; however, the approach to assessing responsive-
ness varied by study, and the base populations tested for
initial responsiveness were not consistent (Table 3).
BH4 was studied in doses ranging from 5 to 20 mg/kg/
day. The follow-up period for the two RCTs was 10 weeks,
and some participants in multiple studies (including the
extension studies) were exposed to the drug for up to
2.6 years. One case series followed participants up to
7 years (Lambruschini et al. 2005), with an average follow-
up of 3.5 years. The mean treatment duration among
participants in another case series (Trefz et al. 2010) was
4 years and 8 months (range ¼ 24–110 months). The
degree to which participants were adherent to a restricted
diet varied. One RCT (Levy et al. 2007) and its follow-on
trial (Lee et al. 2008) included participants with PKU who
were at least 8 years old with a mean age of 20 years,
consuming a relaxed or unrestricted diet, and had baseline
blood Phe level of >450/umol/L. The second RCT
(Trefz et al. 2009) examined the effect of 20 mg/kg/day
for 10 weeks in children ages 4–12 who were on a Phe-
restricted diet with baseline blood Phe levels <480 umol/L.
One uncontrolled open-label study examined a differential
effect in those who maintained a restricted diet versus those
who did not (Vernon et al. 2010).
All randomized trials (Table 4) and three case series
evaluated reduction in blood Phe levels. Two trials and
three case series reported on Phe tolerance (Trefz et al.
2009; Vernon et al. 2010; Burlina and Blau 2009;
Lambruschini et al. 2005; Trefz et al. 2010), and one
cohort study (Humphrey et al. 2011) and one case series
reported on Phe variability (Burton et al. 2010). Only one
case series (Lambruschini et al. 2005) assessed longer-term
outcomes, including cognition and nutritional status. No
study evaluated quality of life. BioMarin, the pharma-
ceutical company that holds the patent for sapropterin
dihydrochloride, sponsored five studies (Burton et al. 2011;
Levy et al. 2007; Lee et al. 2008; Trefz et al. 2009; Burton
et al. 2010), including both RCTs (Levy et al. 2007; Trefz
et al. 2009).
Key Study Results
One good-quality RCT (Levy et al. 2007) randomized 89
participants with PKU to receive either 10 mg/kg of BH4
(N ¼ 42) or placebo (N ¼ 47) once daily for 6 weeks. The
primary outcome was the change in blood Phe from baseline
to week 6. Participants’ mean age was 21.5 years in the
treatment group and 19.5 years in the placebo group.
Table 1 Domains used to assess strength of evidence
Risk of bias: Reflects issues in study design and conduct that could result in biased estimates of effect
Consistency: Reflects similarity of effect sizes seen across studies. Consistency cannot be assessed when only one study is available
Directness: Reflects the relationship between the intervention and the ultimate health outcome of interest
Precision: Reflects the level of certainty around the effect observed
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Adherence to treatment during the 6-week trial was reported
as high, with 82 % of participants taking all doses correctly.
After 6 weeks of treatment, participants in the BH4
group had a significant decrease in mean blood Phe levels
of 235.9  257 mmol/L from baseline (843 mmol/L)
compared with a 2.9  239.5 mmol/L increase in mean
Phe levels from baseline (888 mmol/L) in the control group
(p < 0.0001). The mean blood Phe decreased in the BH4
group at 1 week and remained at that lower level until the
6-week end point, when the mean Phe level was 607 mmol/L.
The estimated difference between treatment and placebo
groups in the mean change in blood Phe at 6 weeks









(Mean baseline Phe level,
mmol/L) Outcomes
Trefz et al. 2009 20 46 4–12 Treatment: 314  107  Phe level
RCT Placebo: 303  74  Phe tolerance
Quality: fair
Levy et al. 2007 10 89 20.4 Treatment: 842.7  299.6  Phe level
RCT (8–49) Placebo: 888.3  323.1
Quality: good
Burton et al. 2011 5–20 90 4–50 613.1  328.5  Phe level
Uncontrolled open labela
Quality: fair
Vernon et al. 2010 10, 20 36 3–58 Restricted diet: 587.0  Phe level
Uncontrolled open label Unrestricted diet:1372.6  Phe tolerance
Quality: good
Lee et al. 2008 5, 10, 20 80 20.4 844  398  Phe level
Uncontrolled open labelb (8–49)
Quality: good
Humphrey et al. 2011 NR 34 Newborn – NR  Tyrosine level
Prospective Cohort Roughly 8  Phe/tyrosine ratio
Quality: poor years  Variability of Phe and
tyrosine levels




Burton et al. 2010 20 37 1.5–32 years 400.2  Phe level
Case series  Phe variability
Quality: poor
Burlina and Blau 2009 10 12 2–16 433–1215 (range)  Phe tolerance
Case series
Quality: poor
Lambruschini et al. 2005 5 14 2.4 months–12 years 382  229  Phe level
 Phe tolerance
Case series  Liberalization of diet




DQ Developmental quotient, IQ Intelligence quotient, N Number, Phe Phenylalanine
a Includes participants from Lee et al. 2008, Levy et al. 2007, and Trefz et al. 2009.
b Open-label continuation of Levy 2007; therefore participants are not unique
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compared with baseline was 245 (p < 0.0002).
A significantly higher proportion of participants receiving
BH4 (44 %) had a 30 % or greater reduction in blood
Phe levels compared with controls (9 %).
Almost all participants (16 of 17) for whom genotyping
was performed had at least one mutation known to be
associated with residual enzymatic activity. Responsiveness











Full text articles excluded
N = 728*
· Not original research 
N = 160
· Not relevant study population
N = 186
· Ineligible study size
N = 273
· Not relevant to key questions
N = 711




Fig. 1 Flow of studies identified for the review. *The total number of articles in the exclusion categories exceeds the number of articles excluded
because most of the articles fit into multiple exclusion categories. BH4 sapropterin, N number
Table 3 Variation in approach to assessing responsiveness to BH4
Study Definition of BH4 Responsiveness % Responders
Humphrey et al.
2011
Reduction in blood Phe of >30 % 15 h after BH4 loading at 20 mg/kg/day NRa
Trefz et al. 2010 Reduction in blood Phe of >30 % after either a 20 mg/kg over 24 h loading test or 20 mg/kg/day
over 8 days
94
Levy et al. 2007 Reduction in blood Phe of 30 % after 8 days of BH4 at 10 mg/kg/day 19.8b
Lee et al. 2008
Burton et al.
2011
Trefz et al. 2009 Reduction in blood Phe of 30 % after 8 days of BH4 at 20 mg/kg/day plus a blood Phe level




Reduction of blood Phe level of at least 30 % or reduction to <360 mmol/L after day 7 on BH4 at
10/mg/kg/day or at 20 mg/kg/day for a total of 30 days
62
(classic PKU ¼ 27,
variant PKU ¼ 100)
Lambruschini
et al. 2005
Reduction in blood Phe of 30 % after 24 h of BH4 at 20 mg/kg/day 19.2
Burlina and Blau
2009





Reduction in blood Phe of 25 % after 2 weeks of BH4 at 20 mg/kg/day or among those with
good control of Phe, an increase of Phe tolerance 200 mg/day by 4 weeks of Rx
NR
NR Not reported, Phe Phenylalanine, PKU Phenylketonuria
a Responsiveness described in Muntau et al. 2002
b Data on responsiveness for this study provided in Burton et al. 2007
c All participants had previously demonstrated responsiveness.
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Table 4 Comparative studies and open-label trials of BH4 for the treatment of PKU
Author, year,
Age, mean





Trefz et al. 2009 G1: 7.7  2.8  Average blood Phe was lowered in the treatment group by
148.5  134.2 mmol/L, compared to a decrease of
96.6  243.6 mmol/L in the control group
20 mg/kg/day once daily compared to placebo G2: 7.1  2.0  Blood Phe levels in the treated group were lower than in the
placebo group by 135.2 mmol/L at week 3 (p < 0.001)
10 weeks  Phe tolerance was increased to 20.9  15.4 mg/kg/day (95 %
CI: 15.4 to 26.4) in the treated group vs. 2.9  4.0 mg/kg/day
in the controls
N ¼ 46
Levy et al. 2007 G1: 21.5  9.5  Average blood Phe lowered in the treatment group by
235.9  257 mmol/L vs. increase of 2.9  239.5 mmol/L in
controls (p < 0.0001)
10 mg/kg/day once daily compared to placebo G2: 19.5  9.8  Estimated difference between groups in mean change in blood
Phe was 245  52.5, with a 95 % CI of 350 to – 141
6 weeks  44 % of the treated group had at least a 30 % Phe reduction
Phe vs. 9 % of controls
N ¼ 89  32 % of the treated group had at least a 50 % Phe reduction
vs. 2 % of controls
Uncontrolled Open-Label Trials
Burton et al. 2011(includes participants from
Levy et al. 2007, Lee et al. 2008, Trefz et al. 2009)
G1: 16.4  10.2  Blood Phe concentrations were within target range for most
subjects
 In 50 % of participants with baseline blood Phe levels above
treatment guidelines, levels were reduced to “within range”
(not defined) during the study
5 – 20 mg/kg/day once daily  Transitory low blood Phe levels (26 mmol/L) were observed
in 4.5 % of subjects while 24 % had blood Phe
levels  120 mmol/L that resolved without any intervention
2.6 years
N ¼ 90
Lee et al. 2008 (extension of Levy et al. 2007) 20.4  9.6
(range 8–49)
 In Phase 1, all three doses (5, 10, 20 mg/kg/day) were
associated with reduction in plasma Phe (p  .01)
Week 1–6 (Phase 1): forced dose-titration (5, 20, and
10 mg/kg/day for 2 weeks each)
 In Phase 2, 37 participants (46 %) showed a decrease in
plasma Phe of at least 30 %, compared with week 0
 In Phase 3, participants had a mean change in Phe from week
0 of 190.5  355.7 mmol/L
Week 7–10 (Phase 2): 10 mg/kg/day  At week 22, at least 30 % reduction in Phe was seen by 46 %
of participants overall (50% of those receiving 5 mg, 49% of
those receiving 10 mg, and 42% of those receiving 20 mg
saw at least 30% reduction in blood Phe)
Week 11–22 (Phase 3): 5, 10, or 20 mg/kg/day based on
Phe concentration at week 2 and 6
22 weeks
N ¼ 80
Vernon et al. 2010 23.4  Nonresponders had a change in blood Phe level of 1422.3 to
1332.6 mmol/L
G1: Completed trial, 29 (range 3–58)  Responders on a restricted diet had a reduction in blood Phe
level from 484.9 to 226.1 mmol/L (p < 0.001)
G1a: Responders, 18  Responders not on a restricted diet had a decrease in blood
Phe level from 1049 to 553.7 mmol/L (p ¼ 0.035)G1b: Nonresponders, 11
Days 1–7: 10 mg/kg/day  Nonresponders on a restricted diet had a change in Phe level
from 1063.7 to 978.7 mmol/L
Days 8–37: 20 mg/kg/day for nonresponders  Nonresponders not on a restricted diet had a mean change in
blood Phe level from 1534.4 to 1465.4 mmol/L
37 days  BH4 responders: 18 (62 %)
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enrolling only those participants who had at least a 30 %
reduction in blood Phe while taking BH4 in a 1-week
loading test, not all participants were responsive to BH4 in
the trial.
A 22-week uncontrolled, open-label trial (Lee et al.
2008) of good quality followed this RCT (Levy et al. 2007)
and included three phases: dose titration, dose analysis, and
a fixed dose phase. All participants enrolled in the previous
RCT were eligible if they had taken at least 80 % of their
scheduled dose in the trial and were willing to continue
their current diet. The primary end point was mean plasma
Phe levels at week 22 and mean changes from week 0. Of
87 participants who completed the previous RCT (Levy
et al. 2007), 80 were enrolled in the extension trial (Lee
et al. 2008), of whom 39 had previously received BH4 and
41 placebo. Participants’ mean age was 20.4 years. High
doses of BH4 (10 or 20 mg/kg/day were more effective at
lowering Phe levels in the dose titration phase. By the end
of the dose analysis phase with 10 weeks at 10 mg/kg/day,
46 % of participants had a decrease in plasma Phe of at
least 30 % compared with week 0. During the fixed dose
phase, most participants (92 %) received either 10 (46 %)
or 20 mg/kg/day (46 %). By week 22, plasma Phe was
reduced by 190.5 mmol/L compared to week 0. Mean
plasma Phe decreased from 844 mmol/L at baseline to
645 mmol/L at week 10 and was maintained at a mean of
652 mmol/L at week 22. At week 22, 46 % of participants
had achieved a 30 % reduction in plasma Phe concentration
compared with week 0. The corresponding reductions for
those receiving 5, 10, and 20 mg/kg/day were 50 %, 49 %,
and 42 %, respectively.
Another RCT (Trefz et al. 2009) of fair quality enrolled
children with PKU between 4 and 12 years of age who
were on a Phe-restricted diet, had maintained blood Phe
control (blood Phe level 480 mmol/L), and had an
estimated Phe tolerance of 1,000 mg/day. The objective
was to determine the safety and efficacy of BH4 at 20 mg/
kg/day for 10 weeks in increasing Phe tolerance (defined as
cumulative increase or decrease in Phe supplement at the
last visit for which blood Phe level was 360 mmol/L)
while maintaining blood Phe control. Participants main-
tained a stable, Phe-restricted diet, monitored by food
diaries. Starting at the third week, a dietary Phe supplement
was added or removed every 2 weeks based on Phe levels.
Children with a blood Phe level of 1200 mmol/L in two
consecutive weeks were withdrawn from study drug
treatment and received dietary counseling.
Thirty-three children were randomized to 20 mg/kg/day
of BH4 for 10 weeks, and 12 children received a placebo.








N ¼ 39  Responders on a restricted diet achieved a Phe tolerance of
41 mg/kg/day compared to a starting tolerance of 21 mg/kg/day
 Two individuals were able to liberalize from a restricted to an
unrestricted diet
Prospective Cohort Studies
Humphrey et al. 2011 Newborn
to < 10 years
 Variation in Blood Phe greater in individuals nonresponsive to
BH4 (responsive to BH4: median 338 mmol/L, 95 % CI:
329–346, mean: 358 mmol/L, 95 % CI 350–366;
nonresponsive to BH4: median 338 mmol/L, 95 % CI
332–344, mean: 370 mmol/L, 95%CI 364–376)
G1: Responders
G2: Nonresponders
Dosage NR  Phe < 400 mmol/L: Responsive to BH4: 66.7 %,
nonresponsive to BH4: 62 %
8 years  Phe > 600 mmol/L: Responsive to BH4: 7.5 %,
nonresponsive to BH4: 12.7 %
N ¼ 34  At Phe >600 mmol/L, median and mean tyrosine levels were
higher among BH4-responsive individuals than those not
responsive to BH4
 Variation in Phe/Tyr ratio greater in individuals nonresponsive
to BH4 (mean ¼ 6.12, 95%CI 5.9–6.3) vs. mean ¼ 5.44
(95%CI: 5.3–5.6) in individuals responsive to BH4,
particularly at Phe > 600 mmol/L
CI Confidence interval, G Group, Phe Phenylalanine, PKU Phenylketonuria, Tyr tyrosine
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Phe supplement tolerated by participants on BH4 increased
significantly from 0 mg/kg/day at baseline to 20.9 
15.4 mg/kg/day. In contrast, the placebo group tolerated
an increase of 2.9 mg/kg/day of Phe supplement. The
adjusted mean difference between the groups in Phe
tolerance was 17.7  4.5 mg/kg/day (p < 0.001). Total
Phe intake (dietary Phe intake plus total Phe supplement)
also increased significantly from baseline in the BH4 group,
approximately doubling to 43.8 mg/kg/day at 10 weeks
compared to a slight increase in total Phe intake in the
placebo group (16.3 mg/kg/day at baseline to 23.5  12.6
at 10 weeks). Mean blood Phe levels decreased signifi-
cantly in the BH4 group between baseline and the
beginning of supplementation in week 3 (decrease of
148.5  134.2 mmol/L). Some participants in the BH4
group had transient low blood Phe levels (<26 mmol/L)
corrected with increased Phe supplementation.
An uncontrolled, open-label trial (Vernon et al. 2010) of
good quality included participants with classic or variant
PKU with any Phe level or diet. Eligible subjects received
7 days of open-label BH4 at 10 mg/kg/day with plasma Phe
measurement on day 8 and weekly during a dietary
modification period with dosage increased to 20 mg/kg/
day until day 30 for nonresponders. Responders who were
on a Phe-restricted diet underwent gradual liberalization of
their diet to the maximum tolerated natural protein intake
while still maintaining plasma levels in the range of 120 to
360 mmol/L.
Of the 29 individuals completing the study, 59 % were
on some form of protein-restricted diet and had a mean
baseline blood Phe of 587 mmol/L. Forty-one percent were
not following protein-restricted diets and had a mean
baseline blood Phe level of 1,372 mmol/L. Overall, 62 %
were determined to be responders, with variable doses
required for response. Four (27 %) of the classic PKU
participants (defined as off-diet plasma Phe of
>1,200 mmol/L) were responders, and 100 % of the variant
PKU participants (>400 and <1,200 mmol/L) were res-
ponders. Of the 12 participants who were not on a Phe-
restricted diet, 33 % were responders with a significantly
decreased mean blood Phe level (554 mmol/L) compared
with baseline (1049 mmol/L). Of the 17 participants who
were on a Phe-restricted diet, 82 % were responders with
significantly reduced mean blood Phe level of 226 mmol/L
compared with baseline (485 mmol/L). Among individuals
who were responders and on a Phe-restricted diet, the
average Phe tolerance increased from 21 to 41 mg/kg/day.
However, responders’ Phe tolerance varied widely from an
increase of 20 to 22 mg/kg/day to a non-protein-restricted
diet in two participants.
One poor-quality prospective cohort study (Humphrey
et al. 2011) assessed variability in blood Phe. Participants
included nine children who were responsive to a 20 mg/kg
BH4 loading test and 25 who were nonresponsive. Among
those who were BH4 responsive, two were treated with
BH4 alone and the rest also needed dietary modifications.
Overall, there were no significant differences in mean and
median blood Phe levels between the groups; however,
above blood Phe levels of 600 mmol/L, confidence intervals
around the mean were wider among BH4 nonresponsive
participants. The authors equate these differences with
variability in response.
Four poor-quality case series (Burlina and Blau 2009;
Lambruschini et al. 2005; Burton et al. 2010; Trefz et al.
2010) evaluated dosages of BH4 ranging from 5 to 26 mg/
kg/day for durations of 6 months to up to 9 years among
BH4-responsive participants. All reported positive out-
comes in terms of reduction in blood Phe and increased
Phe tolerance. One case series (Lambruschini et al. 2005)
also examined longer-term functional outcomes, including
IQ and developmental quotient after 1 year of treatment,
reporting no adverse effects as participants’ Phe tolerance
increased and the diet was liberalized. Nutritional status
was unchanged with the exception of increases in selenium.
In another case series (Burlina and Blau 2009), 12
participants were studied for up to 7 years on a dosage of
10 mg/kg twice a day. In this group, ranging in age from
2 to 16 years old, all participants eventually stopped Phe
supplementation and relaxed dietary restrictions.
Another longer-term case series (Trefz et al. 2010)
assessed Phe levels and increase in Phe tolerance in 16
individuals receiving BH4 for between 24 months to 9 years
(mean ¼ 56 months). The mean blood Phe level in
responders (n ¼ 14) was 321  236 mmol/L, and the mean
decrease in blood Phe was 54.6 % (range 28.4–85.6 %).
Seven patients had stable Phe control without any dietary
restriction. Of the remaining seven patients who were on
dietary restrictions, six increased their Phe intake from a
baseline of 200–300 mg/day to 800–1,000 mg/day.
Psychomotor development among children 5–6 years of
age was reported to be within normal range; however,
results were not presented. One case series (Burton et al.
2010) provided data on Phe variability by measuring blood
Phe at least six times before and after treatment initiation.
Individual variability in Phe levels was lessened after
treatment.
Harms Reported in Studies of BH4
Of the ten studies examining the effectiveness of BH4, four
studies with overlapping participants (Burton et al. 2011;
Levy et al. 2007; Lee et al. 2008; Trefz et al. 2009) reported
any type of harm related to the intervention drug. Three
studies (Burlina and Blau 2009; Lambruschini et al. 2005;
Trefz et al. 2010) reported that no adverse events were
observed during intervention, one study reported that BH4
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was well tolerated with mild diarrhea occurring rarely
(Humphrey et al. 2011), and there was no mention of harms
in two studies (Vernon et al. 2010; Burton et al. 2010). The
most common side effects reported during BH4 trials were
headache, throat pain, upper respiratory infection, diarrhea,
abdominal pain, and nausea and vomiting. Harms probably
or possibly related to study treatment occurred at similar
rates in both BH4 and placebo (23 vs. 20 % (Levy et al.
2007), 27 vs. 25 % (Trefz et al. 2009)) arms in RCTs.
Strength of Evidence
We rated the strength of the evidence (confidence that the
current effect estimate will not change with future research)
for the effects of BH4 on reducing blood Phe levels to
clinically acceptable levels among BH4 responders in the
short term (12 weeks or less) as moderate based on few
studies. The strength of evidence for the indirect relation-
ship of BH4 on IQ is low, based on current evidence and
lack of direct measurement. Harms were noted to be rare
and mild, and the strength of evidence for this observation
is moderate. The strength of the evidence is insufficient for
the direct effect of BH4 on improving all other outcomes
(Phe tolerance and the ability to liberalize the diet, Phe
variability, quality of life, and cognitive and nutritional
outcomes).
Discussion
The treatment for PKU with dietary restriction of Phe in
natural protein and use of Phe-free medical foods has been
critical in reducing the incidence of irreversible neuro-
cognitive impairment in individuals with PKU, and together
with newborn screening has been a tremendous success
story. However, families and patients report that, especially
with the onset of adolescence and adulthood, dietary
adherence and supplement use can be challenging. Little
is known about rates of adherence to diet, and clinicians,
patients, and families have lacked therapeutic options other
than a lifetime of strict dietary management. Importantly,
the ability to liberalize the diet has the potential to affect the
quality of life of individuals with PKU who must be
constantly vigilant about what they consume. Ideally, a
therapeutic adjunct to dietary management would increase
Phe tolerance, allowing for increased intake of dietary
protein and micronutrients, and reducing (but likely not
eliminating) the necessity for Phe-free medical foods.
All studies of BH4 evaluated intermediate outcomes
(change in blood Phe levels and Phe tolerance). Almost no
information is yet available, and none from RCTs studying
longer-term outcomes, including cognitive impairment,
quality of life, nutritional impact and status, and the ability
to liberalize diet. In enriched populations (all participants
had reduced Phe in initial loading tests) with varying levels
of dietary and Phe control, up to half of the participants had
Phe reductions of at least 30 % and the relationship of
reductions in Phe to clinical outcomes was not assessed.
Further, a high proportion of treated participants who
achieved a reduction in blood Phe of the study target of
30 % continued to have Phe levels above the clinical target.
Nonetheless, an open-label extension trial demonstrated
that reductions in Phe observed early in treatment could be
maintained up to 22 weeks (Lee et al. 2008). On the other
hand, the clinical goal for individuals maintaining dietary
control could be to improve their quality of life by
liberalizing their diet. In the trial targeting children with
Phe <480 who were successfully maintaining a restricted
diet, Phe tolerance was increased (Trefz et al. 2009). Even
so, the impact on Phe tolerance was not uniform across the
study population, and although many of the participants
could modestly increase their protein intake, none could be
on an unrestricted diet. Of note, a number of conditions
may affect Phe tolerance, including illness, type of muta-
tion, and degree of BH4 response among others; these are
not assessed in the studies.
In all of the studies, compliance with BH4 was reported
to be good over the short term. However, long-term
sustainability of compliance with both BH4 and dietary
therapy, especially given the variability in response, has not
been evaluated, nor has durability of treatment effects.
Authors from the uncontrolled open-label trial note that one
responder reportedly discontinued BH4 after the trial as the
small increases in Phe intake that BH4 allowed were not
significant enough to warrant taking the medication.
Certainly, observed increases in Phe tolerance were moder-
ate at best in classic PKU in terms of allowing changes in
diet, and the decision about trade-offs between reliance on
medication and carefully titrating liberalization of the diet
will need to be made by patients and their clinicians on an
individual basis that balances available evidence with the
individual’s context.
Even though studies reporting harms consistently indi-
cate that BH4 is well tolerated and without serious side
effects, not all studies assessed and reported harms, and
data are based on a small number of individuals, so ongoing
registries will be important for supplementing these data.
Future Directions
Research on the use of BH4 as an adjuvant therapy in PKU
management is relatively new and consists of small, tightly
controlled multisite efficacy studies. The greatest research
need in this area is thus for larger studies that include
adequate numbers of participants. Given the known diffi-
culty of accruing large numbers of participants, however,
researchers should also use existing data sets and a
consortium and multisite approach to gathering data.
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Ideally, studies will be conducted in both tightly controlled
and nonadherent populations, and among different age
groups, with appropriate design and power for subgroup
analyses. Research should continue to include RCTs, but
prospective cohort studies that may have the potential to
provide additional effectiveness data – including outside of
a controlled clinical setting – adherence, and longer-term
evidence would also be helpful to support understanding of
the role of BH4 in clinical care. These studies should
provide substantially more details on the range of benefits
and harms associated with treatment.
Data are not currently available to understand potential
modifiers of treatment effectiveness in order to select the
best populations for targeting further research and treat-
ment. Moreover, the significant variability in responsive-
ness to BH4 is unexplained, and subpopulations that have a
unique response to this medication have not been well
characterized. Causes of variability may be multifactorial
and likely include individual patient and genotype differ-
ences, drug dose, and individual patient behavior such as
dietary adherence. It is unclear, in particular, why a high
proportion of individuals who have an initial response in
loading studies do not have a durable response even over a
few weeks in efficacy trials, even while those who do have
a response demonstrate a significant effect. The degree to
which this observed variation may be associated with
suboptimal adherence should be assessed both in clinical
trials and other types of studies.
Another area of potential research that could be explored
in combination with studies of BH4 is the use of adherence
supports for both drug and diet to optimize potentially
positive outcomes. Long-term efficacy outcomes beyond
22 weeks and safety outcomes beyond 3 years are currently
unavailable, as are measures of behavioral change and
cognition and patient-reported outcomes including quality
of life. Better markers of treatment effectiveness are
needed; in addition, responsiveness to BH4 with reduction
in blood Phe and improvement in Phe tolerance may not
translate into responsiveness in cognitive outcomes. The
degree to which reductions in blood Phe are associated with
measurable cognitive outcomes or even patient perception
of increased mental clarity is unknown; foundational
research should be done to identify target outcomes for
additional studies. Furthermore, explicit assessment of the
potential for liberalization of the diet, and the subsequent
nutritional effects on cognition has yet to be conducted.
Larger studies are also necessary to determine whether
pharmacologic intervention is more advantageous in certain
age groups or among individuals of varying dietary control
of Phe, genotype, or severity of disease. A number of
studies are reportedly under way to address gaps in the
current literature. These include a long-term study of the
effect of BH4 on neurocognitive function in young
children, a study of the effect in adolescent patients with
attention deficit hyperactivity disorder, and a registry that
includes pregnant women (PKUMOMS).
Conclusions
Dietary management remains the mainstay of treatment for
PKU, and maintaining control over the lifetime is an
appropriate goal. Nonetheless, there is potential for sup-
porting patients in achieving their clinical goals and
possibly liberalizing their diet with adjuvant therapy. BH4
has been shown in two RCTs and three open-label trials to
reduce Phe levels in some patients, with significantly
greater reductions seen in treated versus placebo groups.
We do not yet have the ability to reliably predict which
patients are most likely to be responders, as all participants
in the trials were initially responsive in screening tests, but
not necessarily so in the efficacy studies.
One RCT also demonstrated increased Phe tolerance
using BH4 among children on restricted diets. Overall,
harms associated with the drug were minor and did not
occur more frequently in the treatment group than in
placebo arms. To date, there are no data to directly establish
the potential effects of BH4 on longer-term clinically
important outcomes, including cognition, executive func-
tion, and quality of life. Significant gaps in the evidence
remain, including effectiveness of the drug in a range of
patients outside of the clinical trial setting. Thus, while the
strength of evidence is moderate for a large, positive effect
of BH4 on reducing Phe levels over the short term in
groups of patients showing initial responsiveness, evidence
for the effect of BH4 on longer-term clinical outcomes is
low and based on indirect associations.
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